3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Zimri Hinshaw of BUCHA BIO, Kelly Klein of Easter Seals of Greater Houston, ad John Mooz of Hines. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from esports to biomaterials — recently making headlines in Houston innovation.

Zimri Hinshaw, CEO of BUCHA BIO

Zimri T. Hinshaw, CEO of BUCHA BIO, joins the Houston Innovators Podcast to discuss how he's planning to scale his biomaterials startup to reduce plastic waste. Photo courtesy of BUCHA BIO

After raising a seed round of funding, BUCHA BIO is gearing up to move into its new facility. The biomaterials company was founded in New York City in 2020, but CEO Zimri T. Hinshaw shares how he started looking for a new headquarters for the company — one that was more affordable, had a solid talent pool, and offered a better quality of life for employees. He narrowed it down from over 20 cities to two — San Diego and Houston — before ultimately deciding on the Bayou City.

Since officially relocating, Hinshaw says he's fully committed to the city's innovation ecosystem. BUCHA BIO has a presence at the University of Houston, Greentown Labs, and the East End Maker Hub — where the startup is building out a new space to fit the growing team.

"By the end of this month, our laboratories will be up and running, we'll have office space adjacent, as well as chemical storage," Hinshaw says on the Houston Innovators Podcast. Listen to the episode and read more.

Kelly Klein, development director of Easter Seals Greater Houston

A nonprofit organization has rolled out an esports platform and event to raise awareness and funding for those with disabilities. Photo via Easter Seals

For many video games is getaway from reality, but for those with disabilities — thanks to a nonprofit organization —gaming can mean a lot more. On Saturday Dec. 3 — International Day of Persons with Disabilities — from 1 to 9 pm, Easter Seals Greater Houston will be joining forces with ES Gaming for the inaugural Game4Access Streamathon.

Gaming helps enhance cognitive skills, motor skills, improve mental well-being, and can help reduce feelings of social isolation due to the interactive nature of playing with others.

“This is really a unique way for (people) to form a community without having to leave their house, and being part of an inclusive environment,” says Kelly Klein, development director of Easter Seals Greater Houston. ”The adaptive equipment and specialized technology just does so many miraculous things for people with disabilities on so many levels — not just gaming. With gaming, it is an entrance into a whole new world.” Read more.

John Mooz, senior managing director at Hines

Levit Green has announced its latest to-be tenant. Photo courtesy

Levit Green, a 53-acre mixed-use life science district next to the Texas Medical Center and expected to deliver this year, has leased approximately 10,000 square feet of commercial lab and office space to Sino Biological Inc. The Bejing-based company is an international reagent supplier and service provider. Houston-based real estate investor, development, and property manager Hines announced the new lease in partnership with 2ML Real Estate Interests and Harrison Street.

“Levit Green was meticulously designed to provide best-in-class life science space that can accommodate a multitude of uses. Welcoming Sino Biological is a testament to the market need for sophisticated, flexible space that allows diversified firms to perform a variety of research,” says John Mooz, senior managing director at Hines, in a press release. “Sino is an excellent addition to the district’s growing life science ecosystem, and we look forward to supporting their continued growth and success.” Read more.Read more.

From Your Site Articles
Hines is doubling down on life science real estate development, the firm recently reported. Image courtesy of Hines

Houston-based real estate giant bets on growing life science sector

shifting focus

An international real estate firm announced recently that it would prioritizing investing in life science industry opportunities when it comes to commercial real estate development.

Houston-based Hines reported that the pandemic has heightened the demand for life science real estate, and the firm explained in a news release that it will be delivering purpose-built life science facilities in growing markets that feature state-of-the-art, operator-driven design and amenities.

“The life sciences sector is experiencing an era of unprecedented growth driven by a rise in both public and private funding combined with a post-pandemic sense of urgency and market opportunity,” says David Steinbach, global CIO at Hines, in the release. “As this industry surges, it is pivotal that developers keep pace by delivering spaces that are as innovative as the tenants occupying them. Hines is dedicated to delivering purpose-built facilities that meet the physical, functional and technological needs of the occupiers.”

When it comes to design, Hines will focus on structural specification and the balance of lab and office space, providing tenants — who are all looking or different types of spaces and amenities — with flexibility and modular design.

ESG is something Hines is reportedly considering top of mind for developers, investors and occupiers, with plans to build efficient assets, source from sustainable energy, and provide low-carbon emission options.

Hines has already announced this type of facility currently in construction in Houston. Levit Green is a five-story, 270,000-square-foot Phase I lab building that has flexible Class AA quality labs key features required by top life science tenants. According to Hines, Levit Green's building features will include emergency power sources, 33-foot structural bay depths, allowing for an ideal 11-foot lab module, and floorplates more than 55,000 square feet will also enable research and office teams to create efficient configurations that enable teamwork and collaboration.

“Our carefully built team of national life science leasing, design and capital experts has put a tremendous amount of thought and effort into Levit Green’s planning and design. We are confident that our team will deliver one of the highest-quality commercial laboratory assets in the world once complete,” says John Mooz, senior managing director at Hines, in the release. “We are excited to bring top-tier projects like Levit Green to other highly anticipated, growing markets.”

Boston and San Francisco have become major life science industry hubs, but there are several global cities on the rise that Hines will be targeting, including London, Boulder, Austin, Shanghai Salt Lake City, and Pittsburgh.

Hines’ investment thesis is based on a confluence of factors that are driving the demand within the global landscape for life sciences real estate that are outlined in the new Hines Perspective: “The Potential of Purpose-Built Properties” white paper.

Levit Green is a 270,000-square-foot Phase I lab building adjacent to the Texas Medical Center. Rendering courtesy of Hines

The new building features a waterfront, wharf environment. Rendering courtesy of Hines

Pivotal new waterfront science lab set to cast off in The Medical Center

LEVIT GREEN BLOOMS

The first step of a pivotal new Medical Center district has been revealed. International real estate firm Hines and partner 2ML Real Estate Interests have unveiled the first look at the initial building at Levit Green.

This new, 53-acre life science complex will sit adjacent to the Texas Medical Center. The five-story, 270,000-square-foot Phase I building is designated for life sciences; JLL has been selected as leasing representative for the project, per a press release.

Sitting on the first of several lakes that create Levit Green's oasis, Phase I boasts a sprawling boardwalk environment. Tenants will enjoy waterfront amenities including a 5,800-square foot fitness center and outdoor garden, 7,000-square-foot conference center, 3,500 square feet of café and restaurant space, and on-site parking.

Ground-floor plans include more than 25,000 square feet of lab incubator space, which will provide entrepreneurs and early-stage life science companies top-tier, strategically located laboratory and office space as well as networking opportunities, per a release.

As for the building itself, amenities include: 100-percent-redundant emergency power, enhanced structural vibration attenuation, and augmented mechanical systems. Work on Phase I is slated to begin in the second quarter of this year, with occupancy beginning in Q4.

The 53-acre Levit Green proposed site. Rendering courtesy of Hines

According to data, Houston produces more medical doctorates than any other MSA and generates more research doctorates in the key life science subject areas of biology and physical sciences (chemistry, physics, etc.) than San Francisco, San Diego, and Seattle. Thus, Levit Green promises to solve the real estate demands of arguably the nation's life science capital.

"Houston is quickly emerging as a top life science cluster city and has been able to do so without the purpose-built product established in other locations," said John Mooz, senior managing director at Hines, in a statement. "The Phase I project at Levit Green has been thoughtfully designed from the inside out to include features that are required of a top-tier research environment. We are excited to deliver the highest quality of building that will enable industry leaders to better conduct their critical research."

------

This article originally ran on CultureMap.

The Levit Green development will feature office, research, residential, retail, and dining components, along with outdoor amenities and green space. Image courtesy of Hines

New development announced to rise alongside Houston's Texas Medical Center

now building

Two Houston-based commercial real estate companies — Hines Interests LP and 2ML Real Estate Interests Inc. — have teamed up to develop a 52-acre life-sciences-anchored, mixed-use project adjacent to the Texas Medical Center.

The Levit Green development will feature office, research, residential, retail, and dining components, along with outdoor amenities and green space. In a June 15 release, the developers say Levit Green will sit "at the epicenter of Houston's biotech, corporate life sciences, and medical research hub."

Levit Green will be near the planned TMC³ biomedical research campus. The Hines-2ML project will be built at the northwest corner of Holcombe Boulevard and U.S. Highway 288 on an industrial site that was the headquarters of The Grocery Supply Co. Inc., the predecessor of 2ML.

Being built at a cost of $1.5 billion, the 1.5 million-square-foot, 36-acre TMC³ campus is set for completion in 2022.

"At 15.5 percent, Houston has one of the highest five-year growth rates in life sciences establishments in the United States. Impressive advancements in therapeutics, science, and innovation are driving demand for real estate," John Mooz, senior managing director of Hines, says in the release.

Privately held Hines is a real estate investor, developer, and manager whose portfolio comprises $133.3 billion in assets across 24 countries.

Because Levit Green remains in the master-planning phase, the developers aren't able to provide the project's square footage. They plan to break ground once design work for the initial buildings is finished. The developers decline to disclose a price tag for the project.

"Given the explosive growth and investment in innovation in the life science sector, there is an intense need for state-of-the-art facilities which enable the research required to bring these planned advances into being," Mooz tells InnovationMap in a statement. "As Houston is an ascending life science cluster city, which also includes the world's largest medical center, the need to create facilities that enhance research and development was, to us, obvious."

An initial parcel for Levit Green was purchased by Joe Levit, founder of The Grocers Supply Co., which grew into a major independent wholesaler of groceries in the U.S. and the largest supplier of Hispanic groceries in the U.S. The Levit family owns 2ML.

"Our family has deep roots in the neighborhood, and we believe this development will add tremendous value to the area and the Texas Medical Center," Max Levit, president of 2ML, says in the release.

The Levits entered the retail sector with the purchase of the Gerland's Inc. and Fiesta Mart Inc. grocery chains. In 2014, the family sold its wholesale business and the Grocers Supply name. The following year, the company sold Gerland's and Fiesta Mart.

In conjunction with the sale of the wholesale business and the brand, The Grocers Supply Co. changed its name to 2ML Real Estate Interests. The renamed company controls a portfolio of more than 5.2 million square feet of warehouses, shopping centers, supermarkets, and office buildings. The bulk of 2ML's portfolio is in the Houston area.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings